Pleural effusion - CML - Chronic Myeloid Leukemia
"A pleural effusion is a collection of fluid in the space between the two linings (pleura) of the lung.
When we breathe, it is like a bellows. We inhale air into our lungs and the ribs move out and the diaphragm moves down. For the lung to expand, its lining has to slide along with the chest wall movement. For this to happen, both the lungs and the ribs are covered with a slippery lining called the pleura. A small amount of fluid acts as a lubricant for these two surfaces to slide easily against each other.
Too much fluid impairs the ability of the lung to expand and move."
Extract of Pleural effusion by MedicineNet.com
ARTICLES
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
January 1, 2020, PubMed
The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018, PubMed
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed
Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018
Dasatinib increases endothelial permeability leading to pleural effusion
October 14, 2017, European Respiratory Journal
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
October 2, 2017, PubMed
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
Pleural Effusion: A Rare Side Effect of Nilotinib—A Case Report
September 9, 2014, PubMed
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research Gate
Successful treatment of nilotinib-induced pleural effusion with prednisone.
November 15, 2012, PubMed
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy
March 2011, Haematologica
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily
October 7, 2010, Haematologica
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
September 2007, PubMed
A 50-Year-Old Man With Pleural Effusion and Chronic Myelogenous Leukemia
2006, The Internet Journal of Pulmonary Medicine (Greece)
See also pulmonary arterial hypertension in CML
Return to the List of side effects
Return to Managing Side Effects
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
January 1, 2020, PubMed
The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia
August 12, 2018, PubMed
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
August 9, 2018, PubMed
Maintenance therapy with dasatinib administrated every other day in patients with chronic myeloid leukemia
May 17, 2018, EHA 2018
Dasatinib increases endothelial permeability leading to pleural effusion
October 14, 2017, European Respiratory Journal
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series
October 2, 2017, PubMed
Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity
August 25, 2016, European Respiratory Journal
Pleural Effusion: A Rare Side Effect of Nilotinib—A Case Report
September 9, 2014, PubMed
Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
April 2013, Research Gate
Successful treatment of nilotinib-induced pleural effusion with prednisone.
November 15, 2012, PubMed
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy
March 2011, Haematologica
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily
October 7, 2010, Haematologica
Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia
October 15, 2007, American Journal of Respiratory and Critical Care Medicine
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
September 2007, PubMed
A 50-Year-Old Man With Pleural Effusion and Chronic Myelogenous Leukemia
2006, The Internet Journal of Pulmonary Medicine (Greece)
See also pulmonary arterial hypertension in CML
Return to the List of side effects
Return to Managing Side Effects